Publications by authors named "Pinglan Liu"
Risperidone extended-release injectable suspension (R-ERIS; marketed as RYKINDO) is a novel immediate-release version of risperidone formulated as extended-release microspheres for biweekly intramuscular injection to treat schizophrenia in adults. The pharmacokinetics (PK) and safety of R-ERIS were evaluated in a multicenter, randomized, open-label, multiple-dose study in patients with stable schizophrenia or schizoaffective disorder. Eligible patients (N = 108) 18 to 65 years old were randomized (1:1) to receive IM injections of R-ERIS 25 mg or the comparator, a biweekly risperidone long-acting injectable (BW-RLAI; marketed as RISPERDAL CONSTA) 25 mg for a total of 5 injections.
View Article and Find Full Text PDFArticle Synopsis
- - RYKINDO® is a new long-acting injectable form of risperidone, given biweekly, aimed at treating schizophrenia in adults, and this study aims to compare its effectiveness to RISPERDAL CONSTA® and guide switching patients between these medications.
- - Using pharmacokinetic modeling from phase 1 studies, results showed that Rykindo releases the drug faster than Consta, achieving steady state sooner while maintaining similar drug exposure levels.
- - The study provides recommendations for physicians on how to transition patients from Consta to Rykindo, including timing injections and supplemental oral dosing for those currently on oral Risperdal.
Aims: Rotigotine extended-release microspheres is a weekly intramuscular injection formulation to treat Parkinson's disease. This study aimed to develop a population pharmacokinetics (PK) model for rotigotine extended-release microspheres to investigate its PK ethnic differences.
Methods: Data for the study were obtained from three studies in China, Japan and the US.
Effects of CYP2D6, CYP3A5, and ABCB1 gene polymorphisms on the pharmacokinetics of two risperidone long-acting injection microsphere formulations.
Prog Neuropsychopharmacol Biol Psychiatry
July 2021
Background: LY03004, a novel investigational risperidone long-acting injection (LAI) microsphere formulation, can release risperidone more quickly after injection than Risperdal Consta®. This study aimed to investigate the effects of genetic polymorphisms on the pharmacokinetics of LY03004 compared with those on Risperdal Consta®.
Methods: A total of 100 Chinese patients with stable schizophrenia were randomly assigned to the LY03004 or Risperdal Consta® treatment group.
Adhyperforin is a novel constituent of Hypericum perforatum L., but its antidepressant-like activity remains unclear. To explore that, several well-validated animal models of depression as well as neurotransmitter reuptake and transporter binding assays were conducted.
View Article and Find Full Text PDF[Latent structure model evaluation of syndrome elements and features in 826 hypertriglyceridemia patients].
Zhongguo Zhong Xi Yi Jie He Za Zhi
August 2013
Objective: To evaluate main Chinese medical syndrome elements and features of hypertriglyceridemia patients.
Methods: Using latent structure model (LSM) method, the latent structure diagram of 826 hypertriglyceridemia patients were established. Hypertriglyceridemia syndrome elements and features were interpreted by using latent probability, conditional probability, mutual information, and cumulative information coverage to quantify symptoms/syndromes data,as well as using manual interpretation methods.